Effect of Previous Abdominal Surgery on Laparoscopic Roux-en-Y Gastric Bypass Surgery
In this study, we aimed to investigate the effect of PAS on the feasibility and safety of laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in patients with obesity and type 2 diabetes mellitus (T2DM).
ConclusionOAGB provided very good weight loss, comorbidity improvement, and quality of life at follow-up of ≥ 5 years.
This study compared the effects of laparoscopic Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on hemoglobin A1c (HbA1c) in a predominantly Hispanic and African-American population.
Abstract Background: Bariatric surgery has been shown to induce type 2 diabetes mellitus (T2DM) remission in severely obese patients. After laparoscopic Roux-en-Y gastric bypass (LRYGB), diabetes remission occurs early and independently of weight loss. Previous research has identified preoperative factors for remission, such as duration of diabetes and HbA1c. Understanding factors that predict diabetes remission can help to select patients who will benefit most from bariatric surgery. Methods: We retrospectively reviewed all T2DM patients who underwent laparoscopic sleeve gastrectomy (LSG) or LRYGB between Ja...
ConclusionA high-level of suspicion is required to suspect, diagnose and treat post-RYGB complications. A bariatric on-call rota with appropriately trained personnel is essential.
Conclusionclinicians should be aware of such condition in patients with history of bariatric surgery who present with long-standing, intermittent abdominal pain.
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
ConclusionSynchronous VHR and BS in a bariatric unit is feasible with low recurrence rate. Laparoscopic VHR has lower complication rates than open, apart from seroma formation. Patients with diabetes have higher risk of infection.
Diabetes mellitus is an epidemic disease and is estimated to affect over 300 million people worldwide in 2025 . Type 2 diabetes mellitus (T2D) management is a combination of diet, lifestyle modifications and drug therapy. Recently, many studies had shown remission of T2D in obese population [2-6]. Buchwald et al  in his systemic review and meta-analysis showed that diabetes remission rates were 99% (95% confidence interval (CI), 97-100%) after biliopancreatic diversion (BPD), 84% (95% CI, 77-90%) after Roux-en-Y gastric bypass (RYGB) and 48% (95% CI, 29-67%) after gastric banding.
ConclusionCurrent network meta ‐analysis indicated that BPD or mini‐GBP achieved higher diabetes remission rates than the other procedures. However, the result needs to be interpreted with caution considering that these procedures were in the minority of bariatric surgeries.
CONCLUSIONS: although bariatric surgery continues being the most effective treatment for patients with severe obesity, developing strategies to improve and maintain weight loss, especially in patients with DM2, is fundamental. Assessing the dietary characteristics of candidates for bariatric surgery is crucial. PMID: 30307291 [PubMed - in process]